Scientists from the National Cancer Institute (NCI), part of the National Institutes of Health, together with collaborators from outside academic centers, have developed a checklist of criteria to evaluate the readiness of complex molecular tests that will guide decisions made during clinical trials. The checklist focuses on tests that are based on complex mathematical models incorporating large numbers of measurements from so-called “omics” assays. “Omics” refers to the comprehensive study of sets of related molecules, such as genes, proteins, or metabolites, in a biological sample. Read more here.
Reference: McShane LM, et al. Criteria for the use of omics-based predictors in clinical trials. Nature. 2013 Oct 17;502(7471):317-20. PMID: 24132288
No comments:
Post a Comment